The second study [33] was a prospective study in the United Kingdom and assessed the patient experiences while receiving anti-VEGF treatment for nAMD, measuring clinically significant levels of depression, anxiety, and post-traumatic stress using the Hospital Anxiety and Depression Scale (HADS) [39] and the Impact of Events Scale–Revised [40]. Here, VEGFA is linked to depressive disorder.